AtriCure - ATRC Stock Forecast, Price & News

AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, the company sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

AtriCure Stock Up 2.5 %

NASDAQ:ATRC opened at $51.98 on Monday. The stock has a 50 day moving average price of $43.44 and a 200-day moving average price of $52.72. AtriCure has a one year low of $32.83 and a one year high of $89.18. The company has a debt-to-equity ratio of 0.15, a quick ratio of 2.93 and a current ratio of 3.66. The company has a market capitalization of $2.41 billion, a P/E ratio of 44.81 and a beta of 1.20.

AtriCure (NASDAQ:ATRC - Get Rating) last announced its earnings results on Tuesday, August 2nd. The medical device company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.02). AtriCure had a net margin of 17.62% and a negative return on equity of 11.47%. During the same quarter in the previous year, the firm earned ($0.30) EPS. As a group, equities analysts predict that AtriCure will post -1.09 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on ATRC. Piper Sandler dropped their price target on shares of AtriCure from $90.00 to $55.00 and set an "overweight" rating for the company in a research report on Wednesday, August 3rd. Stifel Nicolaus decreased their price target on AtriCure from $70.00 to $50.00 in a report on Monday, July 18th. Needham & Company LLC upped their price objective on AtriCure from $55.00 to $65.00 and gave the stock a "buy" rating in a research note on Wednesday, August 3rd. StockNews.com raised AtriCure from a "sell" rating to a "hold" rating in a research note on Monday. Finally, BTIG Research lowered their price target on AtriCure from $94.00 to $75.00 and set a "buy" rating on the stock in a report on Friday, June 24th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat, AtriCure currently has a consensus rating of "Moderate Buy" and an average target price of $75.86.